Symbiotec Pharmalab Ltd

Tue 1/09/2026,16:9:6 | NSE : Symbi.Pharma

₹1097.70109.70 (11.10%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 988.00

Previous Close

₹ 988.00

Volume

30102923

Mkt Cap ( ₹ Cr)

₹ 6937.77

High

₹ 1180.00

Low

₹ 934.20

52 Week High

₹ 0.00

52 Week Low

₹ 0.00

Book Value Per Share

₹ 181.93

Dividend Yield

0.00

Face Value

₹ 2.00

What's Your Call?

Collective community sentiment on Symbiotec Pharmalab Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Symbiotec Pharmalab Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Symbiotec Pharmalab - Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider

    1 Sep 2026, 3:42PM Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
  • Symbiotec Pharmalab - Disclosure Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations

    1 Sep 2026, 3:34PM Disclosure regarding authority to determine materiality of event or information.
  • Symbiotec Pharmalab Ltd. debuts with 0.99% discount at Rs 978.20

    1 Sep 2026, 10:00AM Symbiotec Pharmalab Ltd. makes a weak debut on the bourses with scrip got listed at Rs 978.20 on the Bombay Stock Exchange, a 0.99 per cent discount t
  • Symbiotec Pharmalab announces launch of initial public offering

    19 Aug 2026, 5:00PM Symbiotec Pharmalab Ltd. has announced public offering of 17783400 shares at a price of Rs 2.00 each for Cash at a Premium of Rs 986.00 per share. The

Key fundamentals

Evaluate the intrinsic value of Symbiotec Pharmalab Ltd stock 

Name March-23
Assets 780.079
Liabilities 780.079
Equity 10.936
Gross Profit 79.465
Net Profit -22.659
Cash From Operating Activities 93.352
NPM(%) -4.02
Revenue 563.586
Expenses 484.121
ROE(%) -1.97

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Symbiotec Pharmalab Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 871.70 -2.92 22.05 0.00 -26.19 0.57
Lotus Eye Hospital and Institute Ltd 108.77 -0.28 1553.86 0.00 0.39 0.00
Vaishali Pharma Ltd 8.03 -0.37 25.09 0.00 15.42 0.00
Astec Lifesciences Ltd 562.40 0.30 0.00 0.00 -363.14 0.00

Company Info

Our Company wasincorporated as`Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited company, was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025, and a special resolution dated September 12, 2025, passed in the extraordinary general meeting of our Shareholders. Consequently, the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre.Major Events and Milestones:2004- Commenced production of APIs at the Rau Facility2007- Investment by late Rakesh Jhunjhunwala in our Company2009- Received a letter stating that the Rau Facility meets an acceptable state of compliance with cGMP by U.S. FDA2010- Commenced production of APIs including hormone synthesis at the Pithampur Facility- Commissioned a 5 KL biotech plant at the Pithampur Facility- Investment by Franklin Templeton Asset Management (India) Private Limited in our Company2012- Received a letter stating that the Pithampur Facility meets an acceptable state of compliance with the cGMP from the U.S. FDA2013- Investment by Actis Medal Sports Limited in our Company- Commissioned a 35 KL fermentation project at the Pithampur Facility2018- Investment by India Business Excellence Fund- III and Rosewood Investments in our Company2021- Expansion of a sterile plant at the Rau Facility2023- Launched classical fermentation-based APIs at the Pithampur Facility2025- Commissioned a complex injectables facility at the Mhow Facility- Commissioned a 400 KL biomanufacturing facility at the Ujjain Facility

Our Company wasincorporated as`Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited company, was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025, and a special resolution dated September 12, 2025, passed in the extraordinary general meeting of our Shareholders. Consequently, the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre.Major Events and Milestones:2004- Commenced production of APIs at the Rau Facility2007- Investment by late Rakesh Jhunjhunwala in our Company2009- Received a letter stating that the Rau Facility meets an acceptable state of compliance with cGMP by U.S. FDA2010- Commenced production of APIs including hormone synthesis at the Pithampur Facility- Commissioned a 5 KL biotech plant at the Pithampur Facility- Investment by Franklin Templeton Asset Management (India) Private Limited in our Company2012- Received a letter stating that the Pithampur Facility meets an acceptable state of compliance with the cGMP from the U.S. FDA2013- Investment by Actis Medal Sports Limited in our Company- Commissioned a 35 KL fermentation project at the Pithampur Facility2018- Investment by India Business Excellence Fund- III and Rosewood Investments in our Company2021- Expansion of a sterile plant at the Rau Facility2023- Launched classical fermentation-based APIs at the Pithampur Facility2025- Commissioned a complex injectables facility at the Mhow Facility- Commissioned a 400 KL biomanufacturing facility at the Ujjain Facility

Parent Organisation

Symbiotec Pharmalab Ltd.

Founded

20/09/2002

Managing Director

Mr.Anil Satwani

NSE Symbol

SYMBIOTECEQ

FAQ